BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32389672)

  • 21. [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].
    Liu Y; You HY; Yan LZ; Jin S; Shang JJ; Shi XL; Yan S; Yao WQ; Wu DP; Liu W; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):330-335. PubMed ID: 35680633
    [No Abstract]   [Full Text] [Related]  

  • 22. Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.
    Cohen OC; Ismael A; Pawarova B; Manwani R; Ravichandran S; Law S; Foard D; Petrie A; Ward S; Douglas B; Martinez-Naharro A; Chacko L; Quarta CC; Mahmood S; Sachchithanantham S; Lachmann HJ; Hawkins PN; Gillmore JD; Fontana M; Falk RH; Whelan CJ; Wechalekar AD
    Eur Heart J; 2022 Jan; 43(4):333-341. PubMed ID: 34472567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients -  single center experience].
    Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
    Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
    Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
    Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoglobulin light chain amyloidosis associated with multiple myeloma in a young patient: a case report.
    Morais OO; Costa LO; Shinzato DH; Hans-Filho G
    West Indian Med J; 2010 Mar; 59(2):219-21. PubMed ID: 21275130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic light-chain amyloidosis presenting with rapid progressive heart failure.
    Sunbul M; Durmus E; Kivrak T; Besiroglu F; Gerin F; Sari I; Mutlu B
    Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):224-7. PubMed ID: 23868674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognostic factors in light chain amyloidosis].
    Jávorniczky NR; Bodó I; Masszi T; Mikala G
    Orv Hetil; 2015 Sep; 156(39):1577-84. PubMed ID: 26550915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
    Pika T; Lochman P; Vymětal J; Metelka R; Minařík J; Látalová P; Zapletalová J; Bačovský J; Ščudla V
    Klin Onkol; 2013; 26(5):343-7. PubMed ID: 24107157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.
    Lilleness B; Ruberg FL; Mussinelli R; Doros G; Sanchorawala V
    Blood; 2019 Jan; 133(3):215-223. PubMed ID: 30333122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary systemic amyloidosis with delayed progression to multiple myeloma.
    Rajkumar SV; Gertz MA; Kyle RA
    Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of clinical characteristics and outcome of patients with very high risk primary immunoglobulin light-chain amyloidosis].
    Feng J; Huang XF; Zhang CL; Shen KN; Zhang CL; Sun J; Tian Z; Cao XX; Zhang L; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):107-111. PubMed ID: 28279033
    [No Abstract]   [Full Text] [Related]  

  • 32. [The concurrence of light-chain deposition disease, AL-amyloidosis, and cast nephropathy in a patient with multiple myeloma].
    Rekhtina IG; Zakharova EV; Stolyarevich ES; Sinitsina MN; Denisova EN
    Ter Arkh; 2015; 87(6):98-101. PubMed ID: 26281203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kidney and liver involvement in monoclonal light chain disorders.
    Pozzi C; Locatelli F
    Semin Nephrol; 2002 Jul; 22(4):319-30. PubMed ID: 12118397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characterization and outcomes of a cohort of colombian patients with AL Amyloidosis.
    Lacouture Fierro JA; Ribero Vargas DA; Sánchez Cano J; Gaviria Jaramillo LM; Perilla Suarez OG; Galvez Cárdenas KM; Ospina Ospina S
    Colomb Med (Cali); 2023; 54(3):e2025667. PubMed ID: 38107838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.
    Milani P; Dispenzieri A; Scott CG; Gertz MA; Perlini S; Mussinelli R; Lacy MQ; Buadi FK; Kumar S; Maurer MS; Merlini G; Hayman SR; Leung N; Dingli D; Klarich KW; Lust JA; Lin Y; Kapoor P; Go RS; Pellikka PA; Hwa YL; Zeldenrust SR; Kyle RA; Rajkumar SV; Grogan M
    Circ Cardiovasc Imaging; 2018 May; 11(5):e006588. PubMed ID: 29752392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement.
    Saith SE; Maurer MS; Patel AR
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1055-1068. PubMed ID: 33099423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?
    Bahlis NJ; Lazarus HM
    Bone Marrow Transplant; 2006 Jul; 38(1):7-15. PubMed ID: 16715110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.
    Shen KN; Zhang CL; Tian Z; Feng J; Wang YN; Sun J; Zhang L; Cao XX; Zhou DB; Li J
    Amyloid; 2019 Jun; 26(2):66-73. PubMed ID: 31074308
    [No Abstract]   [Full Text] [Related]  

  • 39. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
    Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
    Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.